Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
Billiet, Thomas
Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease. [electronic resource] - Scandinavian journal of gastroenterology Oct 2017 - 1086-1092 p. digital
Publication Type: Journal Article
1502-7708
10.1080/00365521.2017.1339825 doi
Adult
Antibodies--blood
Biomarkers--blood
C-Reactive Protein--metabolism
Crohn Disease--blood
Cytokines--blood
Female
Gastrointestinal Agents--blood
Humans
Induction Chemotherapy
Infliximab--blood
Interferon-gamma--blood
Interleukin-10--blood
Interleukin-6--blood
Interleukin-8--blood
Male
Middle Aged
Serum Albumin--metabolism
Treatment Outcome
Tumor Necrosis Factor-alpha--blood
Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease. [electronic resource] - Scandinavian journal of gastroenterology Oct 2017 - 1086-1092 p. digital
Publication Type: Journal Article
1502-7708
10.1080/00365521.2017.1339825 doi
Adult
Antibodies--blood
Biomarkers--blood
C-Reactive Protein--metabolism
Crohn Disease--blood
Cytokines--blood
Female
Gastrointestinal Agents--blood
Humans
Induction Chemotherapy
Infliximab--blood
Interferon-gamma--blood
Interleukin-10--blood
Interleukin-6--blood
Interleukin-8--blood
Male
Middle Aged
Serum Albumin--metabolism
Treatment Outcome
Tumor Necrosis Factor-alpha--blood